TAGRISSO (osimertinib mesylate)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·EGFR T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER·+2
AstraZeneca Pharmaceuticals
Indication
Non-small cell lung cancer with EGFR exon 19 deletion
Non-small cell lung cancer with EGFR exon 19 deletion is a biologically distinct subset of pulmonary epithelial malignancy defined by specific in-frame deletions within exon 19 of the epidermal growth factor receptor gene. Read more about Non-small cell lung cancer with EGFR exon 19 deletion
4 drugs 2 manufacturers
Drugs that treat it
Common Non-small cell lung cancer with EGFR exon 19 deletion therapies.
RYBREVANT (amivantamab-vmjw)
ANTINEOPLASTIC - BISPECIFIC EGFR AND MET REC INHIBITOR MC AB·NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION·+2
JANSSEN BIOTECH, Inc.
LAZCLUZE (lazertinib mesylate)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION·+1
JANSSEN BIOTECH, Inc.
RYBREVANT FASPRO (amivantamab-hyaluronidase, human recombinant-lpuj)
HYALURONIDASE ENZYMES·NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION·+2
JANSSEN BIOTECH, Inc.
Filter & compare in the drug finder →Opens the drug finder with Non-small cell lung cancer with EGFR exon 19 deletion preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNon-small cell lung cancer with EGFR exon 19 deletion is a biologically distinct subset of pulmonary epithelial malignancy defined by specific in-frame deletions within exon 19 of the epidermal growth factor receptor gene.
Affecting the respiratory system, this subtype is most frequently identified in lung adenocarcinomas and occurs with higher frequency among women, individuals with minimal or no smoking history, and populations of East Asian descent.
Pathophysiologically, these deletions alter the kinase domain near the ATP-binding pocket, leading to ligand-independent, constitutive activation of downstream oncogenic signaling pathways that promote dysregulated cellular proliferation and survival.
As one of the most prevalent classical activating mutations in non-small cell lung cancer, it characteristically predicts heightened tumor sensitivity to EGFR tyrosine kinase inhibitors.
- nih.gov
Non-small cell lung cancer with EGFR exon 19 deletion is a biologically distinct subset of pulmonary epithelial malignancy defined by specific in-frame deletions within exon 19 of the epidermal growth factor receptor gene Pathophysiologically, these deletions alter the kinase domain near the ATP-binding pocket, leading to ligand-independent, constitutive activation of downstream oncogenic signaling pathways that promote dysregulated cellular proliferation and survival As one of the most prevalen...
- lcfamerica.org
Non-small cell lung cancer with EGFR exon 19 deletion is a biologically distinct subset of pulmonary epithelial malignancy defined by specific in-frame deletions within exon 19 of the epidermal growth factor receptor gene Affecting the respiratory system, this subtype is most frequently identified in lung adenocarcinomas and occurs with higher frequency among women, individuals with minimal or no smoking history, and populations of East Asian descent Pathophysiologically, these deletions alter t...
- lung.org
Affecting the respiratory system, this subtype is most frequently identified in lung adenocarcinomas and occurs with higher frequency among women, individuals with minimal or no smoking history, and populations of East Asian descent
- nih.gov
Pathophysiologically, these deletions alter the kinase domain near the ATP-binding pocket, leading to ligand-independent, constitutive activation of downstream oncogenic signaling pathways that promote dysregulated cellular proliferation and survival As one of the most prevalent classical activating mutations in non-small cell lung cancer, it characteristically predicts heightened tumor sensitivity to EGFR tyrosine kinase inhibitors
- nih.gov
As one of the most prevalent classical activating mutations in non-small cell lung cancer, it characteristically predicts heightened tumor sensitivity to EGFR tyrosine kinase inhibitors
Personalize your experience
Follow Non-small cell lung cancer with EGFR exon 19 deletion and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.